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REVIEW OF THE LITERATURE 
Historical Background 
The treatment of head and neck cancer has undergone a 
long evolution. Prior to the turn of the century, surgery 
was the mainstay of therapy. Though many of today's routine 
resections were considered too extensive for that time, the 
first total laryngectomy for cancer of the larynx was per¬ 
formed by Billroth in 1873.* The discoveries of x-rays by 
Roentgen in 1895 and radium by the Curies in 1898 ushered in 
a new era in the treatment of cancer patients. 
In the early 1900's, Crile observed that greater than 
99% of all head and neck cancer patients died from primary 
disease or regional metastases. This led him to perform the 
first radical block dissections of the lymphatics of the neck. 
The three-year disease free interval of his patients increased 
25%. Operative mortality was so prohibitive, however, that 
he limited these resections to cases where the primary was 
in the floor of the mouth and gum,-^ With the development of 
200 kv x-rays in the 1920's, investigators began to appreciate 
the difference in radiosensitivity of many tumors, noting 
that some tumors responded better to surgery while others re- 
4 
sponded better to irradiation. 
The first cure of advanced laryngeal cancer by thera¬ 
peutic radiation was achieved by Regaud, Coutard, and Houtant 
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in 1922.^ In the 1930's, Coutard developed the technique of 
administering radiation in fractionated doses over a period 
of weeks to decrease the local effects. This encouraged fur¬ 
ther use of radiation therapy for head and neck cancers. 
Martin utilized Coutard's technique to irradiate both primary 
and node-bearing areas, and supplemented the external radia¬ 
tion with implantation of radon seeds. Of greater signifi¬ 
cance was the fact that Martin then performed a partial or 
radical neck dissection for persistent disease in the neck, 
signalling the beginning of combined modality therapy. Al¬ 
though supervoltage radiation therapy had developed by this 
2 5 time, it was not met with overwhelming enthusiasm. * ^ How¬ 
ever, in 193^, the publication of a dosage system for gamma- 
6 7 
ray therapy by Paterson and Parker * led to the standardi¬ 
zation of all subsequent radiotherapy. 
The 19^0's, particularly after World War II, saw the 
development of a number of general surgical advances which 
made many radical head and neck procedures safer. These de¬ 
velopments were: sulfa drugs and antibiotics available for 
civilian use, intravenous sodium pentothal anesthesia, endo¬ 
tracheal intubation, blood banks, and the harvesting of split 
thickness skin grafts.-^ Baclesse extended the course of 
radiation therapy from 3 weeks to 6, 8, or 10 weeks, thereby 
further decreasing the amount of acute edema and mucosal 
reaction.2 
In the 1950's there was a resurgence of interest in com- 
8 bined radiation and surgical therapy. New and more powerful 
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sources of radiation were introduced (e.g. Cobalt-60, beta¬ 
tron) to provide large doses to deeper tissue while sparing 
the degree of radiation to skin. Despite an increasing num¬ 
ber of clinical trials employing chemotherapeutic agents, 
accepted therapy has principally remained radiation and 
surgery. 
Cancer of the head and neck region continues to be a 
significant problem to diagnose and treat. In 1976, an esti¬ 
mated 21,400 people died from cancer of the head and neck, 
while approximately 66,000 new cases were reported.^ Many of 
these people will be treated with a combination of radiation 
and surgery, a modality that has been approached with caution 
because of its attendant morbidity during the postoperative 
period. 
Complications of Preoperative Irradiation 
One of the major complications of operating on previously 
irradiated tissue is impaired wound healing. Prior to 1950, 
the risk of postoperative wound complications made the utili¬ 
zation of this combined therapy undesirable, if not prohibi- 
g 
tive. By the late 1950's, however, improvements in both 
radiological and surgical techniques renewed interest in 
this modality and prompted investigators to feel that the 
results outweighed the attendant risks. As reports of the 
results of head and neck cancer treatment with preoperative 
radiation filled the surgical literature, it became evident 
that wound complications still accounted for a major portion 
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of the postoperative morbidity. 
Goldman et al.10 reported on 23 patients with stage III 
cancer of the larynx and laryngopharynx. The patients re¬ 
ceived 5500 rads over 5 weeks, then underwent laryngectomy 
with unilateral or bilateral radical neck dissection between 
3 and 6 weeks after radiation. There were 29 procedures 
performed, resulting in 13 wound complications (45$), which 
consisted of 8 fistulae, 3 infections, and 2 flap necroses. 
Wounds with fistulae took twice as long to heal as wounds 
without fistulae (an average of 3^ days as compared to 1? 
days). As a result of this high complication rate, measures 
were instituted to attempt to reduce the development of fis¬ 
tulae. The next five patients were treated with neomycin 
mouthwash, systemic antibiotics, several days of preoperative 
antiseptic scrubs to the operative site, wound and naso¬ 
pharyngeal suctioning, controlled expectoration of saliva, 
and an oxygen tent; none of these five subsequent patients 
developed a fistula. Although this is meaningless because of 
the small number of patients, it is clear that contamination 
of the wound, particularly from the saliva, was regarded as 
an important factor in the development of fistulae. 
Habel reviewed 463 patients with head and neck cancer 
who had been treated either by combined preoperative radiation 
and surgery (l?2) or by surgery alone (291) during the period 
from 1953-1963. The average radiation dose was 6060 rads; 
the operations were grouped as either radical neck dissection, 
laryngectomy alone, or laryngectomy with radical neck, and 
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the severity of complications in irradiated and non-irradiated 
patients was analyzed in each group. In the absence of com¬ 
plications, no difference was found in healing time between 
irradiated and non-irradiated patients. However, postoperative 
complications in the irradiated group led to an increase in 
healing time of 5®% in the radical neck dissection group and 
100% in the laryngectomy group. There was an overall increase 
in the complication rate among irradiated patients, as well 
as an increase in the severity of their complications; there 
were 5 carotid ruptures (9.7^) and 3 deaths (6%) in the group 
that had undergone laryngectomy and radical neck dissection 
after radiation, compared to 1 death from carotid rupture 
(1.3%) in the non-irradiated group. It was also noted that 
all the carotid ruptures occurred following wound infection. 
The author felt that direct salivary contamination predis¬ 
posed previously irradiated wounds to the development of 
wound infections and subsequent serious complications. 
12 Parnell reported on 12 patients with advanced squamous 
cell carcinoma of the larynx who underwent total laryngectomy 
and radical neck dissection 3 to 6 weeks after a course of 
5000 rads given over 5 weeks. In comparison to an equal 
number of randomized patients who underwent surgery alone, 
the irradiated patients had a markedly increased complication 
rate. Infection, flap slough and fistulae were noted to 
occur commonly in the presence of Pseudomonas. Mouth secre¬ 
tions were implicated in the wound contamination, and the 
possibility was raised of the benefits of neomycin mouthwash 
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without any supporting data. 
1 7 In 1970, Goldman et al. reported on their cumulative 
experience of 53 patients with cancer of the larynx and 
laryngopharynx treated with preoperative radiation. While no 
mention is made of preoperative antibiotic mouthwash or sys¬ 
temic antibiotics, the patients were treated with postopera¬ 
tive penicillin and streptomycin. The incidence of compli¬ 
cations was 46% (41/90 operations), including 19 fistulae, 
10 wound infections, and 3 flap necroses. The authors con¬ 
cluded that "preoperative radiation probably increases the 
surgical and postoperative complications in patients with 
cancer of the larynx and laryngopharynx," while tenaciously 
clinging to the belief that their "preventive" measures had 
"reduced complications to a level which is acceptable and 
more than compensated for by the greater survival rates 
achieved with combined therapy." 
14 Smits et al. studied 193 patients with oral and laryn 
gopharyngeal carcinomas who had undergone irradiation with 
4400-4600 rads over 4 to 5 weeks followed by en bloc resec¬ 
tion and radical neck dissection 4 weeks later. The rate of 
wound infection in this study was 21%, Additional compli¬ 
cations reported were: fistulae, 19#; flap necroses, 12%\ 
carotid rupture, y%. These were usually preceded by wound 
infection. The authors were convinced that salivary leakage 
into the wounds and the flaps predisposed to the formation 
of fistulae. Aggressive maintenance of good oral hygiene 
was considered extremely important; full mouth tooth extrac- 
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tions were performed 5 to 7 days before commencement of radi¬ 
ation therapy. Prophylactic antibiotics were administered, 
careful closure of the wounds, wound suction, and nasogastric 
tube feedings were employed. A year by year analysis revealed 
a decrease in the postoperative complication rate from 45% in 
1967 to 29% in 1971. 
1 5 Backstrom et al. v reviewed 35 patients with carcinoma 
of the tongue who had been given preoperative radiation with 
doses ranging from 3000 to 7000 rads, followed by surgery in 
4-13 weeks. While no difference could be noted in the com¬ 
plication rate among the patients with respect to the time 
interval between radiation and surgery, increasing doses of 
radiation were associated with an increasing frequency of 
complications. No infections, fistulae, or mucosal or bone 
necroses occurred in the 9 patients receiving less than 4000 
rads. 
A similar observation between the dose of radiation and 
the frequency of complications in radical neck dissection 
was noted by Yarington et al.*^ The incidence of major com¬ 
plications in patients who had been irradiated with "curative" 
doses (3500 to 11,800 rads) was 44% (4/9), as compared to 29% 
(2/7) among those who had received planned preoperative radi¬ 
ation (3500 to 4700 rads) and 12% (7/61) among patients under¬ 
going surgery alone. The overall complication rate was 26%, 
most of which occurred in patients who had radical neck dis¬ 
section in combination with oral or pharyngeal resections. 
More recently, Lawrence et al.^ reported on 143 pre- 
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viously untreated patients with stages II-IV squamous car¬ 
cinoma of the oral cavity, oropharynx, or pharynx. Sixty-nine 
patients received 1400 rads in two equal fractions 48 and 24 
hours prior to surgery; all the patients had resection of the 
primary lesion in continuity with a radical neck dissection. 
The incidence of postoperative complications was 24$ (17/69) 
for the irradiated group and 20$ (15/74) for the non-irradi- 
ated group. Though the figures might indicate that a pre¬ 
operative dose of 1400 rads does not lead to a significant 
increase in the postoperative morbidity in selected patients, 
the study showed neither a decrease in the local recurrence 
rate nor an increase in survival with this dose of radiation. 
Clinical experience over the years, then, reveals that 
patients with head and neck cancer are at a high risk for 
complications, particularly wound infection, when they undergo 
radiation therapy prior to surgery. Furthermore, salivary 
contamination has been implicated as a prominent source of 
18 this infection. Shannon et al. have shown that salivary 
flow in patients undergoing radiation therapy (mean dose 
4432 rads) decreases over 6 weeks to 5% of control levels. 
Since saliva plays an important role in suppressing the nor¬ 
mal microflora of the mouth, this effect leads to an altera¬ 
tion of the flora and an increase in the number of pathogenic 
19 
species. Such an alteration in oral contents might be es¬ 
pecially virulent to a healing suture line. Ariyan^® has 
shown that radiated tissue cannot tolerate such bacterial 
contamination as well as normal tissue. In a standard labora- 
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tory model, rats were given single-dose biological equivalents 
of 2300 rads over 2\ weeks, 4000 rads over 4 weeks, and 6000 
rads over 6 weeks. The animals were then wounded at various 
intervals following irradiation, and their wounds innoculated 
4 
with 10 S. aureus. The rate of infection (defined as a 
c 
bacterial count of ICr or more per gram of tissue) increased 
with increasing radiation dosage. There was also a signifi¬ 
cant correlation between incidence of infection and the in¬ 
terval between irradiation and wounding. 
Rationale for Preoperative Irradiation and an Alternative 
In light of the problems with preoperative irradiation, 
the use of postoperative irradiation might be advocated. 
However, the theoretical rationale behind preoperative irra¬ 
diation needs to be considered. One reason for failure of 
head and neck cancer surgery is local recurrence. Recurrence 
rates may be as high as 40-45$. ’ Local recurrence may 
result from any or all of a number of factors: 1) inadequate 
removal of tumor from primary or nodes, 2) local metastasis 
outside the surgical margins, and 3) new primary tumor in the 
area. A fourth possible cause of local recurrence may be 
spillage of tumor cells into the wound during excision. In 
1906, Lawrie wrote: 
"Where the original tumour has been removed 
entire inside a mass or surrounding tissue, like a 
core of paper in a ball of worsted, there will be 
no possibility of transplantation, but where the 
tumour is broken into during an operation the risk 
of transplantation must be very great. In such a 
case small portions conveyed by the fingers or knife 
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might easily find a suitable position on the raw 
surface for renewed growth, hence the so-called 
recurrence." 23 
However, the theory remains extremely difficult to prove. 
21 Smith et al. collected washings from the wounds of 
120 patients with primary operable cancer (all sites) with 
cytological examination revealing definite evidence of tumor 
in 26% of the cases, cells of a suspicious nature in 14$, and 
no evidence of tumor in 60%. Long-term follow up of these 
24 patients revealed no significant differences among the 
three groups as to local recurrence rate. There was, however, 
a significant correlation between local recurrence and de¬ 
velopment of distant metastases, suggesting that seeded tumor 
cells may get into the venous or lymphatic circulation. In 
a similar study of 69 patients with epidermoid carcinoma of 
2 6 
the head and neck, ^ the percentages of washings positive, 
suspicious, and negative for tumor cells were almost identi¬ 
cal (26, 13, and 6l, respectively). The ratio of positive 
to negative washings was greatest when just a wide local ex¬ 
cision of the tumor was performed, less after en bloc resec¬ 
tion including the lymph nodes, and least when a radical 
neck dissection was performed alone. Nevertheless, no sig¬ 
nificant correlation could be found between presence or ab¬ 
sence of tumor in the wound washings and local recurrence. 
Smith's work reportedly showed that washing with saline did 
not prevent tumor implant growth in experimentally seeded 
21 
wounds. Thus, the absence of tumor cells in a wound wash¬ 
ing does not preclude seeding during the operative procedure. 
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Ideally, it would be better to prevent any wound seeding 
and to kill residual tumor before postoperative scarring 
contributed to a decrease in radiosensitivity of the tumor 
g 
cells, or before they had the chance to spread to a distant 
site. It is believed by some that preoperative radiation 
alters tumor cells such that seeding during surgery would 
not result in implantation. To the proponents of this theory, 
an alternative therapy is necessary if preoperative radiation 
were to be abandoned because of its high complication rate. 
It is possible that treatment with methotrexate may fulfill 
this role. 
The clinical efficacy of methotrexate (MTX) in head and 
neck cancer therapy was first demonstrated in 1959 by 
2 6 Sullivan e_t al. Ten of 18 patients showed objective tumor 
regression after continuous intra-arterial MTX infusion con¬ 
comitant with intermittent leucovorin administered intra¬ 
muscularly. Although there are a variety of treatment dosages, 
MTX is still considered by many to be the most effective 
single chemotherapeutic agent for cancer of the head and 
neck,?7 
Methotrexate (4-amino-N1^-methyl-pteroylglutamic acid; 
amethopterin) is a folic acid antagonist. It prevents the 
reduction of dihydrofolate to tetrahydrofdate by competi¬ 
tively binding to the enzyme dihydrofolate reductase. In so 
doing, it blocks thymidylate biosynthesis, effectively pre¬ 
venting incorporation of endogenous thymidine into DNA. 
Therefore, it is cell cycle-phase specific, damaging cells 
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in the “S" phase of division; presumably, its action is en¬ 
hanced in rapidly dividing cell populations. Leucovorin 
(N^-formyl-tetrahydrofolate; folinic acid; citrovorum factor) 
bypasses the block imposed by MTX, because its metabolism to 
tetrahydrofolate does not require dihydrofolate reductase. 
In addition, leucovorin competes with MTX for uptake into 
cells, and it displaces intracellular MTX. Its value as a 
protective agent depends on most of the normal cells of the 
body being in the "Go" (resting) phase, and, hence, not 
susceptible to the action of MTX.^* 
Methotrexate may be administered in high doses either 
intravenously or intra-arterially. The preferred route of 
administration is intravenous, because intra-arterial infusion 
is attended by complications of the catheterization process 
(i.e. cerebrovascular accidents), and because frequently the 
28 32 
tumors extend beyond the area of infusion. * D Intra¬ 
venous infusion is commonly administered over a 24 hour 
period, with leucovorin "rescue" commencing at the end of 
the infusion. Methotrexate is almost entirely excreted in 
the urine in its original form. 
In order to justify the use of MTX as part of a combined 
modality approach to the treatment of head and neck cancer, 
it must be shown that preoperative administration of the 
drug would produce fewer or less severe complications than 
does preoperative irradiation. The major complication of 
preoperative irradiation is impaired wound healing, particu¬ 
larly due to infection and its sequelae. The question that 

must be asked is whether MTX affects wound healing and, in 
particular, whether the treated tissues have a decreased 
tolerance to bacterial contamination. 
Experimental Evidence of the Effect of MTX on Wound Healing 
In 1962 and 1964, papers by Kiehn, DesPrez, and Benson-^* 
referred to investigations of the effect of MTX on wound 
healing in mice. Their conclusions were that wound healing 
was not significantly affected until the systemic dosage ex¬ 
ceeded the LDc-q, and that one week or more should intervene 
between completion of infusion and surgery. The wound heal¬ 
ing data from these studies, however, were never published. 
. 29 
In 1965, Calnan and Davies examined the effect of 
various low-dose schedules of MTX on the tensile strength of 
wounds in rats (see Tables F through H in the appendix). 
Methotrexate was administered intraperitoneally. A dose of 
0.375 mg/kg/day was given for 5 days postoperatively. At 5 
days after wounding, tensile strength was significantly de¬ 
creased to 67% that of controls (p<0.05). When differing 
doses were given (0.125, 0.25, 0.5, and 1.0 mg/kg/day for 5 
days postoperatively, the tensile strength of five-day-old 
wounds decreased with increasing dose, significantly so at 
greater than 0.3 mg/kg/day. A study of pre- and postoperative 
MTX given at a dose of 0.05 mg/kg/day showed that, while 5 
days of postoperative treatment caused a significant decrease 
in the tensile strength of 5-day-old wounds (p<0.05), tensile 
strength was least affected by 5 days of preoperative therapy. 
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The effect of leucovorin "rescue" was also studied. 
Methotrexate was administered at a dosage of 0.5 mg/kg/day 
postoperatively, both alone and with leucovorin 2.5 mg/kg/ 
day. Methotrexate alone significantly depressed tensile 
strength at 3 days and 7 days (p <0.01), but leucovorin 
prevented this completely. At that dosage, leucovorin alone 
produced significantly increased tensile strength at 3 days 
(p<0.01), but by 5 days the effect was no longer significant. 
These experiments were performed at a time when the 
maximum dose for a 60 kg adult was 1.5 mg/kg/day by arterial 
infusion, and 0.15 mg/kg/day by mouth. Leucovorin was con¬ 
sidered to be effective only if given within 4 hours of MTX 
administration. It is difficult to assess how the dosage in 
rats compares to that in humans, but the LD1Q for rats receiv¬ 
ing a 5-day course of MTX I.P. has been calculated to be 
O £ 
0.4-0.6 mg/kg/day. J Significant depression of tensile 
strength, then, occurred with administration of about one 
tenth the LD1Q postoperatively. The effect of varying pre¬ 
operative dosage was not studied, and there was no mention of 
any wound infections. 
In 1975, Cohen et al.-^ investigated the effect of MTX 
on the breaking strength of wounds in mice. Methotrexate 
was administered intraperitoneally as a single dose of 80 mg/kg 
(in this study, equivalent to 0.6-0.8 of the LD^q in BDF^ 
mice) immediately after wounding. Breaking strength was 
measured at 3, 7, and 21 days (see Table I in the appendix). 
At 3 days, wound breaking strength was significantly impaired 
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(p<0.05), but by 7 days •wound strength had returned to control 
levels, where it remained through 21 days. None of the ani¬ 
mals developed wound infections. 
The aforementioned two studies employed different 
methods of measuring wound integrity, tensile strength and 
breaking strength. Tensile strength cannot be assessed with 
validity in the first week postoperatively, as tensile 
strengths during that time tend to be too small for accurate 
measurement. Breaking strength would appear to be a more 
valid measurement, especially if one were interested in the 
wound's potential for dehiscence. Unfortunately, since Cohen 
did not test a variety of doses and dose schedules, his ex¬ 
perimental design has little correlation to clinical use of 
MTX. 
It is clear that MTX has a deleterious effect on wound 
healing, even in low doses, and particularly when administered 
postoperatively. One has no way of knowing whether much 
higher doses than those tested would lead to further decreased 
wound healing or other wound complications. The clinical 
significance of these observations with regard to head and 
neck cancer surgery would depend not only on the dosage and 
time of administration relative to sugery, but also on the 
presence of contamination from oral contents, thought to be 
the major causative factor in wound complications in pre¬ 
viously irradiated patients. 
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Surgical Complications of Preoperative Methotrexate 
In 1962, Kiehn et al.reported on a series of patients 
treated with intra-arterial MTX infusion. The MTX dose was 
50 mg/day for 6-7 days, with concomitant injections of 
leucovorin 6 mg I.M. every 6 hours. Systemic complications 
included leukopenia in some patients (one patient developed 
severe leukopenia and died of fulminant pneumonitis). How¬ 
ever, local complications dominated the picture, developing 
in approximately 50% of the patients who were treated for 
palliation by infusion alone. Nine patients were treated 
with combined chemotherapy and surgery; wound complications, 
consisting of wound breakdown, separation, and infection oc¬ 
curred in 5 patients who were operated on within two weeks 
following completion of the infusion. In one patient, in¬ 
fection following radical neck dissection led to carotid 
rupture. No wound complications occurred in 2 patients who 
underwent surgery 3 and 6 weeks, respectively, following in¬ 
fusion, or in 2 patients whose surgery preceded infusion by 
2 weeks. 
Kiehn’s clinical impression was that "the drug had a 
noxious effect on the wound." The high incidence of infec¬ 
tions and breakdown of catheter sites was felt to be secondary 
to the high concentration of the drug. The local complica¬ 
tions made subsequent neck dissections more difficult. With 
the catheter placed in the temporal artery, wound complications 
were reduced. 
In 1964, DesPrez et al.-^ reviewed 13 patients with 
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head and neck cancer who had been treated with preoperative 
MTX, 50 mg/day for 7-10 days by intra-arterial infusion 
(temporal artery) with concomitant leucovorin 6 mg I.M. every 
6 hours, and surgery performed at an unspecified time after¬ 
ward. Wound complications included 4 fistulae and 1 wound 
separation (38%). The wound separation occurred in a patient 
who was operated on the day following completion of his in¬ 
fusion. 
37 In 1975, Tarpley ej; al. reported on a series of 30 
patients with epidermoid carcinoma of the head and neck. 
They received an intravenous MTX infusion of 240 mg/m over 
24 hours, followed by leucovorin, 75 mg I.V. over 12 hours, 
then 12 mg I.M. every 6 hours for 4 doses. Two days later, 
this regimen was repeated. Surgery was performed 5-8 days 
following completion of the second infusion. Systemic 
toxicity was not severe. Postoperative complications in¬ 
cluded 3 wound infections, 2 orocutaneous fistulae, 4 pneu¬ 
monias, and 13 fevers greater than 38°C. When compared to 
an equal number of retrospectively selected controls, no in¬ 
crease in postoperative morbidity was demonstrated. However, 
studies comparing retrospective controls are not very valid 
or revealing. 
Arlen^ employed both MTX and radiation preoperatively 
in the treatment of 50 patients. A fractionated course of 
2000 rads was delivered to the primary site and node-bearing 
areas. After an unspecified interval, MTX was administered 
intravenously at a dose of 240-500 mg/m over 24 hours. 
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Leucovorin was then begun with 75 mg I.V. over 12 hours, then 
25 mg I.M. every 12 hours for 4 doses. This regimen was re¬ 
peated. Surgery was performed 3-5 days after completion of 
the second infusion. Six patients developed severe stomatitis, 
but Arlen denied any interference with wound healing by the 
preoperative therapy. However, he did not report his com¬ 
plications. Regardless of whether MTX or radiation were re¬ 
sponsible for wound complications, the lack of controls or 
statistical analysis makes evaluation of his claim difficult. 
In summary, laboratory investigations of MTX administra¬ 
tion has shown a significant effect on wound healing, even 
in small doses; larger doses may show greater effects. The 
literature on clinical experience indicates that after a high- 
dose infusion of the drug, infection is a major component of 
postoperative wound complications in head and neck cancer 
patients. Though the clinical studies dealing with high- 
dose intravenous infusion do not suggest that morbidity is 
increased, as do earlier studies, their techniques leave cer¬ 
tain questions unresolved, and, as such, cannot be properly 
evaluated at this time. 
Kiehn commented that "factors other than infusion of 
the drug may have influenced the development of the compli- 
33 
cations," yet no one has attempted to identify any contri¬ 
butory factors, other than "technique."In light of the 
complications with preoperative irradiation discussed above, 
it would be logical to ask whether MTX causes decreased re¬ 
sistance to bacterial contamination of a surgical wound. A 
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well controlled clinical investigation in head and neck 
cancer patients would be difficult to achieve, as a result 
of the great variability in presentation of the tumors, the 
effects of previous unsuccessful therapy, and the presence of 
an abundant microflora within the oropharynx. Therefore, a 
good laboratory model is necessary. This study examines the 
effect of high-dose MTX on the ability of wounds to tolerate 
bacterial contamination. It further evaluates the optimal 
time that may be necessary between treatment and wounding to 
achieve normal healing. 
In selecting the dosage of MTX, the intent was to ad¬ 
minister a dose large enough to kill all the rats, yet not 
so lethal as to prevent rescue by leucovorin at 24 hours. 
It was also hoped that serum MTX levels would approach the 
_ C 'iQ 
"therapeutic range" (10->n)^ , albeit transiently. Our pre¬ 
liminary work established that 300 mg/kg of MTX was lethal 
to 50-100% of the rats, and that mortality was reduced to 
30% after 100 mg/kg of leucovorin administered at 24 hours. 
Higher doses of MTX were more consistently lethal, but 
leucovorin could not rescue sufficient numbers of rats to 
make use of these doses feasible. 
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MATERIALS AND METHODS 
Animals 
One hundred twenty-eight 6-week-old, male, Sprague- 
Dawley rats (Charles River Laboratories, Kingbridge, Mass.), 
weighing 165-197 g (average 181.4 g), were used. Rats were 
fed a standard laboratory pellet diet and tap water ad libitum. 
Drugs 
Methotrexate (sodium salt) and leucovorin (calcium salt) 
were obtained from the National Cancer Institute, Drug Syn¬ 
thesis and Chemistry Branch. Methotrexate was stored in a 
refrigerator, and leucovorin was deep-frozen at -80°C. All 
solutions were prepared immediately prior to use. 
Methotrexate was dissolved in sterile saline and the 
pH adjusted with 10M NaOH to approximately 8.5. Final con¬ 
centration was 20 mg/ml. It was administered intraperitoneally, 
as a single injection, at a dose of 300 mg/kg. 
Leucovorin was dissolved in sterile water to a concen¬ 
tration of 10 mg/ml. It was administered intraperitoneally, 
as a single injection, at a dose of 100 mg/kg. 
Bacteria 
Coagulase positive Staphylococcus aureus, cultured from 
a human specimen on chocolate agar, were obtained from the 
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Bacteriology laboratory of Yale-New Haven Hospital. A single 
colony was subcultured on sheep blood agar, and all innocula 
were obtained from this resultant pure culture. Cultures for 
innoculation were prepared in thioglycollate broth and incu¬ 
bated for 20-24 hours before use. Doses of bacteria in in¬ 
nocula were checked by backplating. 
Serum Methotrexate Levels 
Certain animals were selected for determination of 
serum MTX activity (see below). Blood was obtained by random 
cardiac puncture with a 19-gauge needle, transferred to a 
red-topped Vacutainer tube, allowed to clot, and then centri¬ 
fuged at approximately 2000 rpm for 10 minutes. The serum 
was aspirated with a Pasteur pipette and then frozen for 
assay at a later time. Methotrexate activity was determined 
40 
using the dihydofolate reductase method. 
Anesthesia 
R Animals were anesthetized with Pentosol (sodium pento¬ 
barbital, 6.5$) I.P., approximately 50 mg/kg. An anesthesia 
death was considered to be a death occurring within two hours 
of I.P. injection. 
Wounding 
On the appropriate days after leucovorin administration 
(see below) groups of rats were anesthetized, their backs 
were shaved, and they were strapped prone to dissection boards. 
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The dorsum of each animal was prepped with Betadine solu¬ 
tion. 
A sterile #10 scalpel was used to make a 2 cm longi¬ 
tudinal incision. The incision was made to the right of the 
midline, in a cephalad-caudad direction, from 4 cm to 2 cm 
above an imaginary line joining the iliac crests. The inci¬ 
sion was carried through the skin and panniculus carnosus 
and into the paraspinous musculature. Bleeding was controlled 
by pressure with gauze. 
Wounds were then innoculated with either 0.1 ml sterile 
saline or 0.1 ml thioglycollate broth calculated to contain 
10^ S. aureus (see below). The skin and panniculus were then 
closed in one layer with three interrupted sutures of 5-0 
R 
Ethicon black, monofilament nylon on an FS-2 needle, and in¬ 
strument tied with four knots. The wound in the musculature 
was not sutured. In every group, animals designated to re¬ 
ceive saline innocula were wounded before those animals desig¬ 
nated to receive innocula of S. aureus. Following wounding, 
rats were returned to their cages. Bacteria-innoculated ani¬ 
mals were isolated from saline-innoculated animals, and MTX- 
injected animals were caged separately from non-MTX-injected 
animals. No dressings were applied. 
Biopsy 
All animals were biopsied four days after wounding. 
Animals that received saline innocula were biopsied before 
those that received S. aureus. The rats were anesthetized, 
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but they were neither shaved nor prepped. Using a #10 scal¬ 
pel, an incision was made at least 2 cm lateral to the ori¬ 
ginal wound. Subpannicular dissection was carried out to 
the previous incision in the paraspinous musculature. Under 
aseptic conditions, a portion of fascia overlying this in¬ 
cision, approximately 0.8 cm x 0.8 cm, was excised. 
Each specimen was placed on a separate piece of powder 
paper (glassine). Then it was flamed, weighed, and ground 
in a sterile tube with a sterile pestle, after being diluted 
1 to 10 with thioglycollate broth. Growth of a single or¬ 
ganism from 0.1 ml of the contents of the tube would be 
2 
equivalent to 10 organisms per gram of specimen. Serial 
dilutions were done in thioglycollate broth to produce blood 
2 
agar plates which could be read for bacterial counts of 10 , 
4 6 8 10 , 10 , and 10 organisms per gram. Plates were read after 
24 hours of incubation at 37°C. 
White Blood Count 
After biopsy, each animal was laid supine, the thorax 
cut open with a scissors, and at least 1 ml of blood was as¬ 
pirated from the heart under direct visualization. The blood 
was transferred to purple-topped Vacutainer tubes (contain¬ 
ing EDTA) and sent to the Hematology laboratory of Yale-New 
Haven Hospital for automated white blood cell count. 
Experimental Procedure 
One hundred eight rats were injected with MTX. Nine of 
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these rats were set aside to observe the lethality of the dose. 
An additional 9 were sacrificed (in groups of 3) at 4, and 
8 hours following injection, and their sera assayed for MTX 
activity. The remaining 90 rats were injected with leuco- 
vorin 24 hours after MTX injection. 
Twenty rats were injected with sterile saline I.P. in 
lieu of MTX and leucovorin, in comparable volumes by weight. 
Methotrexate- and non-MTX-injected rats were caged 
separately. Animals receiving MTX and leucovorin were iso¬ 
lated from those receiving MTX alone. 
Rats were divided into 5 groups (Groups I-V). Groups 
were wounded 1, 3, 7, 14, and 28 days, respectively, following 
leucovorin (or sham leucovorin) injection. Each Group con¬ 
sisted of 22 rats: 18 MTX- and 4 non-MTX-injected animals. 
Wound innoculation in each group was carried out as follows: 
# of rats 
15 
3 
2 
2 
I.P, injection 
MTX 
MTX 
Saline 
Saline 
Innoculum 
S. aureus 
Saline 
S. aureus 
Saline 
Wound biopsy, for quantitative bacterial count, and white 
blood cell count were performed on all animals four days 
after wounding. 
Statistical Analysis 
Analyses were performed of quantitative bacterial 
counts and white blood cell counts using a two-tailed student's 
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4i 
"t" test of two independent means. Statistical significance 
of bacterial counts was computed using the logs of these 
2 
values. A count of <10 organisms/g was assigned a value of 
1.0. 
In each Group, the relationship of elevated bacterial 
counts to elevated WBC1s was assessed by calculation of the 
41 
Pearson product-moment correlation coefficient. Again, 
lop;s of the quantitative counts were used in these deter¬ 
minations . 
Identification of Bacteria 
S. aureus was distinguished by medium-sized, whitish 
colonies surrounded by zones of beta-hemolysis. Two forms 
of contaminant were encountered. One was typified by small, 
greyish-white colonies, without hemolysis, resembling S. epi- 
dermidis. These were seen occasionally, though never in 
great numbers. The other contaminant was typified by large, 
irregular, greyish colonies, resembling several gram negative 
species. These were seen rarely. 
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RESULTS 
Serum Methotrexate Levels 
Serum MTX levels at 4, and 8 hours after injection 
are recorded in Table 1. When these values are plotted 
(Figure 1), they do not describe the complex plasma persis- 
42 
tence curve seen by Borsa et al. in mice. This may be due 
either to the initial erratic absorption from the peritoneum, 
to a difference in metabolism and excretion between the spe¬ 
cies, or to the small number of rats used here. 
*MTX 500 mg/kg 
(modified from 
Borsa e_t al. 42 ) 
2 ‘ 3 ' k ‘ ' k ' 7 ' k 
Time after injection (hrs) 
9 
—i_ 
10 
FIGURE 1 
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METHOTREXATE LEVELS 
Time Rat # Serum Concentrat 
! hr 106 3.17xlO”6M 
107 8.47x10~6M 
108 9.17x10“^ 
4 hrs 1 3.53x10”7M 
2 6.11x10“7M 
3 7.76x10“7M 
8 hrs 4 3.17x10~8M 
5 3.17x10~8M 
6 2.59x10"8M 
TABLE 1 
Toxicity/Lethality 
There were 4 deaths out of 9 rats that received MTX 
without leucovorin (44.4$). Deaths occurred 1, 3, and 7 (2) 
days following MTX administration. Toxic manifestations in¬ 
cluded weakness, lethargy, and disheveled appearance. Blood 
was also noted in the feces. Animals that survived demon¬ 
strated these signs to a lesser extent, if at all. 
Two deaths occurred in rats that received MTX and leuco¬ 
vorin (#'s 26 and 40). These deaths occurred at 8 and 6 
days, respectively, following MTX injection. Rat #40 had 
undergone no procedures (i.e. wounding); it is presumed that 
MTX toxicity was the cause of death. Rat #26 had been wound¬ 
ed and innoculated with S. aureus 3-4 days before its death. 
While it is altogether possible that it may have succumbed 
to MTX, death secondary to sepsis cannot be ruled out. 
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Susceptibility of rats to fatal intoxication from single 
doses is known to be variable. ^ This may reflect differences 
in absorption, state of hydration, and metabolism. 
Anesthesia Deaths 
There were 2 anesthetic deaths. 
The terms to be used in this report with regard to the 
4 groups of rats are: 
a) MTX-Staph: rats injected with MTX and leucovorin; 
wounds innoculated with S. aureus 
b) MTX-Saline: rats injected with MTX and leucovorin; 
wounds innoculated with saline 
c) Saline-Staph: rats injected with saline; wounds 
innoculated with S. aureus 
d) Saline-Saline: rats injected with saline; wounds 
innoculated with saline 
All raw data are presented in the appendix, Tables A through E. 
Quantitative Bacterial Counts 
One hundred two rats were wounded. One rat, #26, died 
3-4 days after wounding and innoculation with S. aureus. Its 
death was due either to MTX toxicity or to septicemia. There 
were 4 dehiscences. These all occurred in MTX-Staph rats. 
One hundred one biopsies were performed. No gross pus was 
evident in any wound. Seventeen wounds grew out >10^ organisms 
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per gram of tissue. All bacterial counts of >103 organisms/g 
were from MTX-Staph rats. 
The distribution of quantitative counts with respect to 
time of wounding following MTX-leucovorin administration is 
recorded in Table 2 and displayed graphically in Figure 2. 
Twenty-seven percent of the MTX-Staph rats had bacterial 
counts of>103 organisms/g. Sixty-nine percent of counts 
were <103, 53% were <10 , and 23% were <103. In contrast, 
100% of the wounds of control rats (MTX-Saline, Saline-Staph, 
and Saline-Saline) had quantitative counts of<103 organisms/g, 
86$ of the wounds had counts which were <10^, and 66% were 
<103. 
In Group I, 33.3% (5/15) of the MTX-Staph rats grew out 
>103 organisms/g. Twenty percent (3/15) of wounds dehisced 
in the MTX-Staph group; two of these subsequently grew out 
>10^ organisms/g, and one grew out <10 . Analysis of the 
logs of the quantitative counts of the MTX-Staph rats showed 
them to be significantly higher than both those of the Group 
I controls (p<0.05) and those of the ten Saline-Staph rats 
(p <0.001). Although the bacterial counts of the Group I 
MTX-Saline rats were all<103, they were still significantly 
higher than those of the ten Saline-Staph rats (p<0.01) and 
also those of the ten Saline-Saline rats (p<0.02). 
In Group II, 21.4$ (3/1^-) of the MTX-Staph rats grew 
out ^103 organisms/g. There was one dehiscence; this wound 
c 
grew out >10^ organisms/g. The quantitative counts of the 
MTX-Staph rats were significantly higher than those of the 
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Group II controls (p<0.05), but there was no significant 
difference compared to the ten Saline-Staph rats. 
In Group III, 64.3$ (9/14) of MTX-Staph rats grew out 
>105 S. aureus/g. At the time of biopsy, the wounds of this 
experimental group demonstrated granulomata. These were not 
found in any of the controls. Bacterial counts of the MTX- 
Staph rats were significantly higher than both those of the 
Group's controls (p <0.001) and those of the ten Saline-Staph 
rats (p <0.001). 
Although wound innocula were calculated to be 10^ S. 
aureus, it was found, on backplating, that rats in Group IV 
4 
received only 10 bacteria in their wounds. None of the rats 
in this Group grew out >10^ S. aureus. In fact, all the 
r> 
wounds cleared the bacteria to 6x10 J or less. No significant 
elevation of bacterial counts was found. 
All quantitative counts in Group V were reduced to 3x10^ 
or less per gram. Although counts of this MTX-Staph group 
were significantly higher than those of its simultaneous con¬ 
trols (p <0.05), there was no statistical difference between 
these MTX-Staph rats and the ten Saline-Staph rats. 
There was no statistically significant difference among 
the three control groups (MTX-Saline, 15 rats; Saline-Staph, 
10 rats; Saline-Saline, 10 rats) with respect to quantitative 
bacterial count. 
White Blood Cell Count 
Although the mean white blood count of the MTX-Staph 
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rats in Group I was less than the mean of the Saline-Staph 
rats, the difference was not significant. There was, how¬ 
ever, an inverse correlation between the quantitative counts 
and the WBC's; that is, higher bacterial counts correlated 
with lower white blood counts (p<0.05). 
In Group II, WBC1s of the MTX-Staph group did not differ 
significantly from those of any control group. 
White cell counts of the MTX-Staph rats in Group III 
were generally elevated and were significantly higher than 
those of the Group's simultaneous controls (p <0.001), as 
well as those of the Saline-Staph group (p <0.001). There 
was a direct correlation between high quantitative counts 
and high white blood cell counts for the 21 rats of Group III 
(p <0.001), but there was no significant correlation between 
bacterial counts and white cell counts of the 14 MTX-Staph 
rats. 
In Group IV, five MTX-injected rats were not wounded, 
in order to serve as additional controls for WBC's. The MTX- 
Staph group had significantly higher white counts than these 
controls (p<0.05), although there was no significant dif¬ 
ference when compared to these rats plus the 3 MTX-Saline 
control rats. There was no significant difference between 
the white cell counts of the MTX-Staph rats and those of all 
Group IV control rats, nor was there any difference in com¬ 
parison to the Saline-Staph group. 
White counts of the Group V MTX-Staph rats were not sig¬ 
nificantly elevated, but a direct correlation was again seen 
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between quantitative counts and white blood cell counts for 
both the MTX-Staph rats (p<0.02) and the entire Group (p<0.02). 
There was no significant difference among the MTX-Saline 
group, the Saline-Staph group, and the Saline-Saline group 
with respect to white blood cell count. 
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DISCUSSION 
The presence of more than 10^ bacteria per gram of 
tissue has been shovTn to be associated with clinical infec- 
44 tion and wound breakdown. Therefore, the term "wound in¬ 
fection" shall henceforth refer to the case where biopsy of 
a wound contains more than 10^ organisms per gram of tissue. 
In this experiment, then, 26% of rats given high-dose 
MTX and leucovorin, and subsequently wounded and innoculated 
with subinfective doses of S, aureus, developed wound infec¬ 
tions. All infections occurred in rats wounded within one 
week following leucovorin administration (or, eight days 
after MTX), a 40% wound infection rate for MTX-Staph rats 
during that period. All dehiscences occurred in Groups I and 
II, which was a rate of 14% of the wounds made within four 
days of injection of MTX. It is likely that the one rat 
that had a count of <10^ bacteria had originally developed 
a wound infection, causing this dehiscence. Rats in the MTX- 
Saline, Saline-Staph, and Saline-Saline control groups had 
no infections, and there were no dehiscences. 
This experiment clearly shows that MTX has a deleterious 
effect on the host's ability to tolerate wound contamination. 
In order to understand exactly how MTX impairs this tolerance, 
an understanding of the host's natural defense mechanisms is 
essential. 
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Normally, the initial barrier to infection is the epi¬ 
thelial surface with which bacteria come into contact. The 
dryness of the skin, its lysozyme content, and the presence 
of bactericidal fatty acids in sebaceous secretions all 
afford protection from bacterial invasion. In the respiratory 
44 tract, cilia and mucus remove particulate matter. Poly¬ 
morphonuclear leukocytes abound in the mucous membrane of the 
oropharynx, and IgA antibodies in nasal secretions and saliva 
19 
agglutinate bacteria for more effective phagocytosis. Acidity 
plays an important role in preventing bacteria from establish- 
44 ing themselves in the alimentary and genito-urinary tracts. 
Once the epithelium has been incised, by a scalpel, for 
example, the systemic defense mechanisms are evoked. These 
are the processes of inflammation, humoral immunity, and 
cell-mediated immunity. They attempt to contain and resolve 
the infectious process. 
Acute inflammation is a non-specific response to tissue 
injury. It begins with constriction of venular sphincters, 
mediated by certain vasoactive amines, notably histamine and 
bradykinin. This eventually produces increased vascular 
permeability and the leakage of protein-rich fluid into the 
tissues. Blood leukocytes adhere to the endothelium of the 
venules and capillaries and then emigrate via the widened 
4 5 interendothelial junctions. ^ Chemotaxis is effected by by¬ 
products of the complement system, especially C5 fragments, 
46 
and by clumps of bacteria. In the early stages, infiltra¬ 
tion is predominantly by neutrophils, reflecting their high 
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percentage in the peripheral blood. However, because of the 
short half-life of neutrophils, their numbers in the inflam¬ 
matory exudate are gradually replaced by mononuclear cells, 
44 
which become tissue macrophages. 
Neutrophils phagocytize the bacteria. They are aided 
in this process by specific antibody molecules and complement. 
These plasma proteins act as opsonins with most bacteria, 
i.e. they coat the organisms and promote effective phagocytosis. 
Leukocytes have surface receptors for antibody (Fc receptors) 
and complement (C3 receptors). Bacteria are destroyed in 
intracellular vaculoes by lysozyme, hydrogen peroxide, and 
myeloperoxidase. Macrophages are also effective against the 
microbes, although they may utilize different enzymes from 
44 46 
the neutrophils. ’ 
Even though destruction of bacteria occurs primarily 
at the site of innoculation, a number of organisms are drained 
by the lymphatics to regional nodes. Here cortical dendritic 
macrophages partially degrade the bacteria and couple them 
to preformed RNA. The RNA is brought into contact with 
small lymphocytes, which undergo a morphologic transformation 
to large lymphoblasts. A wave of proliferation starts ap¬ 
proximately 24-48 hours after introduction of the bacteria 
and lasts four to 14 days. Proliferation of large lymphoblasts 
yields large numbers of four different classes of cells. 
These are: 1) committed large lymphoblasts, 2) plasma cells, 
3) differentiated effector small lymphocytes, and 4) memory 
small lymphocytes. 
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Humoral immunity, the immunity conferred by antibody, 
originates with the large lymphoblasts and plasma cells. 
Large lymphoblasts appear at the site of specific antigen 
localization, in this case a bacterial innoculum, from four 
to 10 days after immunization. They crawl between endothelial 
cells and produce antibody locally. Plasma cells remain in 
the node and produce most of the circulating antibody. Two 
major classes of circulating antibody are produced. IgM (19S) 
production peaks at one to two weeks and generally subsides 
by 28 days. IgG (7S) production supplants that of IgM and 
30 
may continue for months or years. Antibody may combine 
with complement to directly cause lysis of certain strains 
of gram negative bacteria, but, as noted above, with most 
46 • bacteria they act as opsonins. 
Effector small lymphocytes are responsible for cell- 
mediated immunity. They localize at an antigen site, under¬ 
go lymphoblastoid transformation, and produce several factors 
that attract macrophages to and localize them at the antigen 
site. They also recruit non-immune lymphocytes and are direct- 
30 ly cytotoxic to foreign cells. Cell-mediated immunity 
does not play an important primary role in defense against 
bacterial invasion (M. tuberculosis and M. leprae are two of 
the exceptions). However, the ability of the body to mount 
a delayed hypersensitivity reaction correlates with morbidity 
and mortality from sepsis. A normal cutaneous response is 
associated with a low incidence of morbidity from infection, 
partial anergy with increased morbidity and mortality, and 
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total anergy is associated with a high incidence of mortality 
47 from infection. 
Memory small lymphocytes recirculate through the body, 
providing immunologic surveillance. On reexposure to antigen 
they undergo lymphoblastoid transformation and mount a 
30 
"secondary immune response."^ 
Effect of MTX on the Local Inflammatory Response 
That MTX produces a decrease in the peripheral WBC is 
well known. Rats injected with 50 mg/kg of MTX show a pro¬ 
gressive decrease in the number of circulating granulocytes 
and lymphocytes. The granulocytes are affected to a greater 
43 48 
extent, producing a relative lymphocytosis. Condit 
demonstrated a biphasic response in humans. After I.V. bolus 
injection of six to 16 mg/kg, total leukocyte counts reached 
minimum values in four to seven days and recovered to normal 
I 
levels in seven to 13 days. In 75% of cases, recovery was 
followed by a second depression of white counts to new minimum 
values 12-21 days after MTX injection. These values were 
often lower than during the first depression. Final recovery 
took anywhere from 15-29 days. These variations essentially 
reflected changes in the number of circulating neutrophils; 
the absolute number of lymphocytes varied very little. Maxi¬ 
mum leukopenia in the second week after MTX therapy was also 
49 60 
noted by Hersh ert al. * J Shortly after treatment, the 
circulating neutrophils are hypersegmented, like those seen 
in megaloblastic anemia. These may take as long as one month 
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to disappear.^ 
Depression of the peripheral white blood count merely 
reflects concomitant changes in the bone marrow. The number 
of proliferative cells decreases with increasing doses of 
MTX, until a plateau is achieved. This plateau represents 
between 30% and 60% of normal numbers of myeloid precursors.^’ 
Repeated doses of MTX (every four hours) are able to reduce 
the number of proliferative cells even further. Granulo¬ 
cyte precursors are predominantly affected. As the lifespan 
of the granulocyte in the circulation is much shorter than 
that of the lymphocyte, many more cells in the granulocyte 
precursor pool undergo DNA replication over a given time 
period, hence their greater susceptibility to MTX and the 
relative and absolute neutropenia observed in the peripheral 
blood.^ 
The ability of the MTX-depressed marrow to mobilize 
granulocytes in response to infection was studied by 
c c 
Constable and Blackett. J Rats were treated with MTX 5 mg/kg. 
At various intervals afterward, 60 j»g of Salmonella typhosa 
endotoxin were injected I.V., and eight hours later the num¬ 
ber of granulocytes in the peripheral blood was examined. 
Endotoxin response reached a minimum at four days after MTX, 
with recovery to control levels by seven days. At nine days 
there was an overshoot to three times the control value, 
after which the response decreased to normal values at about 
16 days. In this experiment, a similar phenomenon was ob¬ 
served with respect to white blood cell counts of the MTX- 
53 
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Staph rats. Group I rats, biopsied 6 days after MTX injection, 
had a mean WBC of 4131. By 8 days, white counts averaged 
5385. However, Group III MTX-Staph rats, biopsied on day 12 
after MTX, had a mean WBC of 15,82?. Nineteen days after 
MTX, average WBC1s had returned to 7700 (Group IV). These 
data are plotted in Figure 3 alongside Constable's response 
curve and white counts of the respective MTX-Saline controls 
in the present experiment. (Note: WBC1s in the present 
experiment were drawn four days after bacterial innoculation, 
as compared to eight hours in Constable's study.) The num- 
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ber of mobilized granulocytes reflects the size of the pool 
of mature neutrophilic cells in the bone marrow. The nadir 
at four days corresponds to the time myeloblasts take to 
mature into segmented neutrophils; thus, the myeloblast is 
probably the granulocyte precursor cell most sensitive to 
MTX.^ 
The neutrophil phase of the inflammatory response is 
diminished only when the number of granulocytes in the peri- 
3 30 pheral blood is below 1000/mnr. The lowest white blood 
cell count of any MTX-Staph rat was 1500/mrrP, and only two 
of the rats that developed wound infections had WBC1s less 
than 2000 cells/mm . Without differential counts, however, 
we do not know the absolute number of neutrophils represented. 
These two rats probably had less than 1000 granulocytes. 
Nonetheless, the highest infection rate in any Group occurred 
in the presence of adequate leukocytosis (Group III). How¬ 
ever, leukocytes produced at this time may be functionally 
defective. MTX is known to be ineffective in compromising 
the metabolism of normal leukocytes, in contrast to its 
72 
action on acute lymphatic leukemia cells. Therefore, there 
must be other factors contributing to the susceptibility to 
infection. 
Hersh e_t al. studied the local inflammatory response 
in man by means of the skin window technique. Patients re¬ 
ceived either "intensive" or "intermittent" MTX, and skin 
windows were placed 24 hours after cessation of therapy. 
When differential counts of the inflammatory exudate were 
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performed, they showed a significant decrease in the percent 
of mononuclear cells compared to controls (see Table J in 
the appendix). The absolute cellularity at four and eight 
hours approximated that of controls, but at 24 hours total 
cellularity was clearly depressed (an increased number of 
neutrophils notwithstanding). Recovery was substantial by 
five days. The inhibition of mononuclear cell exudation 
did not correlate with numbers of circulating cells. Leuko¬ 
penia and stomatitis developed after the skin viindow tests 
and persisted for three weeks. Four patients developed in¬ 
fections, including two pneumonias, one pharyngitis with 
septicemia, and one pharyngitis with furunculosis (see Table 
K in the appendix). All these patients had very depressed 
24-hour mononuclear cell exudates. 
It is clear that the mononuclear cell plays an important 
role in combatting infection. Impaired mononuclear cell 
exudation also predisposes to the development of Candida 
albicans infection, even in the face of normal humoral and 
cell-mediated immunities. Oral candidiasis is a problem 
57 
not infrequently seen during MTX therapy. 
4 The mechanism of mononuclear cell exudation is unknown. 
trp 
It is not dependent on the presence of neutrophils. 
59 Page^ showed that the process is dependent upon both RNA 
and protein synthesis. He hypothesized that a substance 
produced at the site of tissue injury was required by the 
lymphocyte to initiate mRNA and protein synthesis before the 
lymphocyte could migrate into the extravascular compartment. 
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MTX has been shown to significantly inhibit the actions of 
several vascular permeability factors.^ Since these proteins 
46 
are not strictly "chemotactic", they may be the substances 
of Page's theory. It seems unlikely that the moderate 
effect of MTX on protein synthesis^* is responsible for such 
great inhibition. 
Methotrexate, then, is a potent inhibitor of the in¬ 
flammatory response. It depresses the bone marrow, producing 
a decrease in circulating granulocytes, and it delays mono¬ 
nuclear cell exudation by several days. In addition, MTX is 
able to directly inhibit the action of certain factors of 
vascular permeability. However, it is not known whether 
leukocyte function is impaired. 
Effect of MTX on Humoral Immunity 
The local inflammatory response comprises the first 
line of defense against invading bacteria. A deleterious 
effect of MTX on humoral immunity would mean the loss of the 
opsonization function of both local and circulating antibody. 
The ability of MTX to inhibit cell proliferation would, in 
theory, make it an effective immunosuppressive agent. 
The first investigation of the effect of MTX on humoral 
62 immunity was carried out in 1952 by Malmgren e_t ad. Mice 
were injected with sheep red cells intraperitoneally and 
then treated with a five day course of MTX. Antibody levels, 
measured by hemolysin titers, decreased with increasing 
dosage. There was complete absence of antibody effect after 
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a dose of 1.5 mg/kg/day s.c. There was no inhibition of pre¬ 
formed antibody, either in vitro or in vivo. This suggests 
that MTX acts at the site of antibody production. 
Berenbaum ^ studied the effect of a single injection of 
MTX on the antibody response of the mouse to T.A.B. (Typhoid- 
paratyphoid A and B) vaccine. Significant depression of 
antibody levels occurred when MTX was injected one to two 
days after vaccination. This would correlate with the wave 
of proliferation of large lymphoblasts in the node. Antibody 
levels remained depressed for several weeks afterward. There 
was no effect if MTX was injected before the vaccination, 
and there was also no effect on established antibody levels. 
Berenbaum later expanded upon this model to examine the pro- 
61 
tective effects of leucovorin. He found that administra¬ 
tion of leucovorin betvreen one hour before and one hour after 
MTX injection prevented the deleterious effect of MTX on 
antibody production. Antibody levels were partially depressed 
if leucovorin was delayed for two hours, but a delay of six 
to eight hours afforded no protection. 
64 Santos and Owens found that mean peak antibody 
titers were significantly depressed, except when the sheep 
red blood cells were injected either five days or more before 
the start of MTX or two days or more after the completion of 
a five day course of MTX. They subsequently demonstrated the 
correlation of these effects with 19S and 7S antibody pro¬ 
duction (see Table L in the appendix).^ Otterness and Chang^ 
demonstrated in mice that MTX injected as a single dose at 
I 
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the time of immunization was inactive in suppressing anti¬ 
body synthesis. 
The immunosuppressive effect of MTX has also been 
49 
studied in humans. Hersh e_t al. exposed patients on 
"intensive" MTX therapy (daily for five days) and "intermit¬ 
tent" MTX therapy (every fourth day) to Vi antigen, tularemia 
vaccine, and pneumococcus Type III polysaccharide. The 
antigen was administered during their courses of therapy, 
and ?1% of patients on intensive MTX therapy and 50% of patients 
on intermittent therapy showed complete suppression of anti¬ 
body response. In a follow-up study, they demonstrated the 
return of normal antibody response when the antigen was ad¬ 
ministered three days after the completion of MTX therapy.^0 
Mitchell e_t al. ' studied the response of a series of patients 
receiving intermittent high-dose MTX and leucovorin rescue 
to E. coli Vi antigen and tetanus toxoid. Antigens were ad¬ 
ministered immediately prior to the start of therapy, and 
as long as infusions were continued, there was complete sup¬ 
pression of all antibody synthesis. After therapy, 55% of 
patients recovered antibody synthesis within 20 days, which 
suggests that MTX does not interfere with the initial recog¬ 
nition of antigen by lymphoid cells. 
Methotrexate, therefore, is a potent inhibitor of anti¬ 
body production, but the critical element is the timing of 
administration of the drug relative to the introduction of 
an antigen. Maximum antibody suppression is seen when MTX is 
injected two days after the antigenic stimulus. When the two 
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events occur simultaneously, MTX has no effect when given as 
a single injection, but a continuous course will suppress 
antibody production. In the present study, MTX was injected 
at least 48 hours before any antigenic stimulus (S, aureus). 
The results of previous experiments would indicate that there 
should be no effect on the production of antibody. However, 
none of the aforementioned studies administered as high a 
dose of MTX prior to immunization as in the present experi¬ 
ment. Whether or not the dose used in this experiment would 
suppress antibody production remains still in question. 
Effect of MTX on Cell-Mediated Immunity 
The effects of MTX on cell-mediated immunity are similar 
to its effects on humoral immunity. Otterness and Chang^ 
demonstrated the inhibition of a primary cellular immune 
response vThen antigen was administered during a course of 
MTX therapy. As a single dose at the time of immunization, 
88 
though, MTX was inactive. Medzihradsky e_t al. found MTX 
to be most effective in suppressing both complement-dependent 
and complement-independent cellular immunity when adminis¬ 
tered two days after the antigenic stimulus. Complement- 
independent cellular cytotoxicity, the kind associated with 
delayed hypersensitivity, was sensitive to the administration 
of MTX four days before immunization. However, the appear¬ 
ance of delayed hypersensitivity has been shown by Hersh e_t 
al. ^ and Mitchell e_t a/l.^ to be unaffected by MTX, both 
during and after a course of the drug. 
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Methotrexate, therefore, is able to inhibit all three 
aspects of the systemic host defenses. It appears that only 
the effects on the inflammatory response are of consequence 
to the present study because of the relative timing of MTX 
administration and bacterial innoculation. 
In addition to the inhibitory effects on the host defense 
mechanisms, MTX may promote wound infection by otherwise de¬ 
laying wound healing. For example, bone marrow depression 
may lead to thrombocytopenia and ineffective hemostasis. 
Extravascular blood clots and hematomas predispose to in- 
69 fection. Clinically, though, thrombocytopenia has not been 
vo 48, 51 
a problem. * v 
While bacteria may be directly introduced into a viound, 
erosion of the oral mucosa and gut epithelium secondary to 
MTX would expose the tissues to ambient flora, leading to 
44 bacteremia and seeding of the operative viound. This may 
account for the gram negative "contaminants" encountered 
in viound biopsies. 
In the ’’proliferative phase" of wound healing, there is 
rapid division of fibroblasts, and epithelial and endothelial 
cells. MTX is known to inhibit rapidly dividing cell popu¬ 
lations. However, by analogy to the immune system, pre¬ 
operative MTX probably does not affect these cell lines. 
The effect of MTX on the proliferative phase is most likely 
due to its effect on the inflammatory phase. Since the pro- 
70 liferative phase begins when the inflammatory phase ends,' 
and since MTX is so effective at inhibiting and prolonging 
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the inflammatory phase, then the effect of MTX on the pro¬ 
liferative phase is to delay its onset. This may be respon¬ 
sible for the observed experimental effects of MTX on wound 
healing, discussed above. 
The role of the neutrophil in wound healing, aside from 
defense, is controversial. It has been proposed that neutro¬ 
phils generate electronically excited singlet molecular oxy- 
71 gen to aid in proline hydroxylation. If this is so, then 
MTX-induced neutropenia and any functional limitations im¬ 
posed on neutrophils by MTX might delay wound healing. 
Finally, MTX has associated hepatic and renal toxicities. 
Both uremia and hepatic disease lead to depressed wound heal- 
69 ing and an increased risk of infection. 
At this point, some of the experimental results become 
more explicable. For instance, the elevated bacterial counts 
of the MTX-Saline rats in Group I were the result of the 
rats' decreased tolerance to their own skin flora. Two days 
after MTX injection white counts were probably dropping (by 
day six, one was still 3500; unfortunately, the other two 
samples clotted). Perhaps the number of granulocytes was 
less than 1000/mm . A severely inhibited inflammatory re- 
2 3 
sponse would allow the 10 -10^ bacteria per gram that inhabit 
the surface of the skin to flourish, if only moderately, but 
to levels significantly above normal. 
Another interesting phenomenon is the incidence of 
wound separation. Twenty percent of MTX-Staph rats wounded 
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two days after MTX therapy sustained wound dehiscence. In 
Group II (four days after MTX) , the rate of wound separation 
was 7%. By seven days (Group III), there were no dehiscences, 
even in the face of the highest infection rate (64$). All 
rats that suffered wound separation had white blood cell 
counts at the time of biopsy less than or equal to 3^00 cells 
3 
per mm . The interplay of inflammatory response and wound 
integrity becomes evident. Having less than an adequate 
number of granulocytes and a strongly inhibited mononuclear 
cell exudation, the rats are highly susceptible to establish¬ 
ment of infection. Significant tensile strength in a wound 
69 does not appear until well into the proliferative phase. 
However, as long as the stimulus to inflammation is present 
and a response not forthcoming, proliferation will not begin. 
Eventually, the bacteria overwhelm the paltry local defenses, 
and the wounds separate. 
As the rats recover from the neutropenia and the de¬ 
layed inflammatory response, the incidence of wound infection 
should decrease. A possible explanation for why it does not 
may be that the neutrophils released in the "overshoot" (see 
above), although mature morphologically, are somehow immature 
functionally. A defect in chemotaxis, binding of complement 
and antibody, phagocytosis, or intracellular digestion would 
allow infection to be maintained. After another week, the 
bone marrow returns to the production of functionally com¬ 
petent neutrophils. 
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CONCLUSION 
^he results of this experiment indicate that rats 
treated with a dose of methotrexate in the LD^Q range and 
rescued with leucovorin 24 hours later have a decreased 
tolerance to controlled contamination of surgical wounds. 
The fact that none of the uncontaminated wounds became 
infected demonstrates the importance of bacterial contam¬ 
ination in the pathogenesis of wound complications seen 
clinically in the postoperative period. In the head and 
neck cancer patient, saliva is an obvious source of such 
contamination. 
Rats were at increased risk for infection only when 
they were wounded and innoculated within one week of MTX- 
leucovorin therapy, which supports the clinical impressions 
of Kiehn and DesPrez. This suggests that the optimal time 
interval betvreen MTX therapy and surgery which would achieve 
normal wound healing and the lowest incidence of wound in¬ 
fection would be at least two weeks. 
The experimental design employed herein can be expanded 
to examine the efficacy of systemic and/or topical anti¬ 
microbials for prophylaxis or treatment. Such studies might 
establish further guidelines for future clinical trials. 
Preoperative administration of MTX may prove to be a 
very effective regimen in the treatment of head and neck 
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cancer. However, prior to the institution of such combined 
modality therapy, awareness of any and all attendant risks 
is essential. It is hoped that this study will contribute 
to that goal. 
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GROUP I 
Rat f Quantitative Count WBC 
MTX-Staph 
7 6xl04 6000 
8 5xl03 X 
9 6x10^ - dehiscence 2100 
10 2x10^ - dehiscence 1500 
11 1x10^ 6300 
12 3x10^ 2200 
13 5x10^ 3000 
14 5xl03 - dehiscence 3400 
15 5xl03 7000 
16 8x10^ 2800 
17 
4 3x10 1800 
18 5x103 6800 
19 lxl 0^ 5100 
20 
4 
2x10 5700 
21 5xl07 X 
MTX-Saline 
82 5xl04 X 
83 4x104 3500 
84 4 5x10 X 
Saline-Staph 
109 lxl O-5 X 
110 6xl02 X 
Saline-Saline 
119 
4 
7x10 X 
120 <io2 X 
X denotes sample clotted 
TABLE A 
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GROUP II 
Rat ff Quantitative Count WBC 
MTX-Staph 
22 1x10 1900 
23 
4 1x10 4300 
24 2xl03 4700 
25 7xl03 9200 
26 Dead by day 8 after MTX 
2? 5xl05 6400 
28 lxlO6 4700 
29 1x10° - dehiscence 3600 
30 Contaminated 5900 
31 <102 7100 
32 4xl03 4600 
33 7xl02 7200 
34 8xl02 3600 
35 <102 X 
36 3x104 6800 
MTX-Saline 
85 9xl02 5500 
86 lxlO3 8900 
87 3xl02 3400 
Saline-Staph 
111 2x10^ X 
112 <102 X 
Saline-Saline 
121 lxlO2 5000 
122 7xl02 5500 
X denotes sample clotted 
TABLE B 
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GROUP III 
Rat # Quantitative Count WBC 
MTX-Staph 
37 2x10' 10,300 
38 3x10^ 15,100 
39 
4 1x10 10,400 
40 Dead by day 6 after MTX 
41 3x1 (P 25,400 
42 5xl08 18,900 
43 lxl 08 13,600 
44 2xl05 14,700 
45 6xl06 15,200 
46 6xl04 X 
47 2x104 8600 
48 IxlO5 X 
49 2x10^ 26,300 
50 5xl06 15,600 
51 6x10^ X 
MTX-Saline 
88 7xl02 14,600 
89 8x102 7500 
90 6xl02 7400 
Saline-Staph 
113 1x10^ 4700 
114 
4 
2x10 8100 
Saline-Saline 
123 2x108 6000 
124 lxlO3 5600 
X denotes sample clotted 
TABLE C 
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GROUP IV 
Rat # Quantitative Count WBC 
MTX-Staph 
52 2xlOJi 7800 
53 1x10^ 7000 
54 lxlO3 X 
55 6xl02 7400 
56 2xl03 8000 
57 6xl03 8600 
58 Contaminated 11,500 
59 lxlO3 X 
60 lxlO3 4500 
61 3xl03 6800 
MTX injection; no wound 
62 5700 
63 4700 
64 5600 
65 X 
66 5200 
MTX-Saline 
91 <102 6200 
92 5xl02 9300 
93 3xl03 8200 
Saline-Staph 
115 8x10^ 8200 
116 6xl02 5800 
Saline-Saline 
125 lxlO2 7700 
126 2xl03 X 
X denotes sample clotted 
TABLE D 
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GROUP V 
Rat # Quantitative Count WBC 
MTX-Staph 
67 lxlO2 4800 
68 1x102 5200 
69 3x10^ X 
70 102 X 
71 6xl02 12,500 
72 6xl02 8300 
73 1x10^ 9100 
74 lxlO3 9800 
75 Anesthesia death 
76 3xl02 8100 
77 5xl02 10,900 
78 6x102 6600 
79 Anesthesia death 
80 lxl 02 6800 
81 
2 
10 X 
MTX-Saline 
94 
2 
10 7100 
95 102 4100 
96 102 X 
Saline-Staph 
117 1x10 7300 
118 lxlO2 9100 
Saline-Saline 
127 2x102 7500 
128 lxlO2 7900 
X denotes sample clotted 
TABLE E 
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Effect of Increasing Doses of MTX on Wound Tensile Strength 
(Tensile strength measured at 5 days) 
Dose of MTX Tensile Strength (g) 
0,125 mg/kg/day 88 
0.25 mg/kg/day 81 
0.5 mg/kg/day 63 
1.0 mg/kg/day 39 
Controls (saline) 114 
TABLE F 
(adapted from Calnan and Davies2^) 
Effect of Pre- and Postoperative MTX on Wound Healing 
(Tensile strength measured at 5 days) 
Treatment Tensile Strength (g) 
0.05 mg/kg/day for 5 days preoperatively 144 
0.05 mg/kg/day for 5 days pre- and 
5 days postoperatively 133 
0.05 mg/kg/day for 5 days postoperatively 122 
Controls (saline) 15^ 
TABLE G 
(adapted from Calnan and Davies2^) 
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Protective Effect of Leucovorin 
Tensile Strength (g) 
Treatment 3 days 7 days 
MTX 0.5 mg/kg/day 13 111 
MTX 0.5 mg/kg/day plus 
leucovorin 2.5 mg/kg/day 46 228 
Leucovorin 2.5 mg/kg/day 61 238 
Controls (saline) 36 220 
TABLE H 
29 (adapted from Calnan and Davies 7) 
Effect of MTX on Wound Healing 
Breakin g Strength (g) 
Day 7 Day 21 
MTX 80 mg/kg 64+4 127±7 495±35 
Controls 77+5 131+7 553+24 
TABLE I 
(modified from Cohen et al. ) 
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Effect of MTX on 19S and 7S Antibody 
Production in the Rat 
Beginning of MTX Administration* 
Two days after immunization** 
Five days after immunization 
Seven days before immunization 
19s 7S 
Decreased, Absent 
but prolonged 
Prolonged Decreased, 
with 
delayed 
recovery 
Prolonged No effect 
*MTX 0.75 mg/kg I.P. qd x 5 
**1.0 ml of 10% sheep erythrocytes I.V. 
TABLE L 
(adapted from Santos and Owens^) 
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